3 Stocks Underperforming Today In The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 7 points (0.0%) at 16,563 as of Tuesday, Aug. 12, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,349 issues advancing vs. 1,605 declining with 179 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Abbott Laboratories ( ABT), down 1.2%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.1%, HCA Holdings ( HCA), down 0.7%, St Jude Medical ( STJ), down 0.6% and Aetna ( AET), down 0.5%. Top gainers within the industry include Smith & Nephew ( SNN), up 1.6%, Intuitive Surgical ( ISRG), up 1.4%, WellPoint ( WLP), up 0.9%, Cigna ( CI), up 0.8% and Boston Scientific ( BSX), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.31 (-0.9%) to $35.21 on light volume. Thus far, 214,326 shares of Grifols exchanged hands as compared to its average daily volume of 705,700 shares. The stock has ranged in price between $34.83-$35.45 after having opened the day at $35.42 as compared to the previous trading day's close of $35.52.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $12.2 billion and is part of the health care sector. Shares are down 1.7% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, robust revenue growth, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Brookdale Senior Living ( BKD) is down $0.68 (-2.0%) to $32.79 on average volume. Thus far, 804,580 shares of Brookdale Senior Living exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $32.74-$33.40 after having opened the day at $33.40 as compared to the previous trading day's close of $33.47.

Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates in six segments: Retirement Centers, Assisted Living, Continuing Care Retirement Communities (CCRCs) Rental, CCRCs Entry Fee, Brookdale Ancillary Services, and Management Services. Brookdale Senior Living has a market cap of $4.2 billion and is part of the health care sector. Shares are up 23.1% year-to-date as of the close of trading on Monday. Currently there are 6 analysts that rate Brookdale Senior Living a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Brookdale Senior Living as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full Brookdale Senior Living Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Agilent Technologies ( A) is down $0.63 (-1.1%) to $54.57 on average volume. Thus far, 1.1 million shares of Agilent Technologies exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $54.33-$55.07 after having opened the day at $55.00 as compared to the previous trading day's close of $55.20.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $18.4 billion and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B

Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B

5 Big Dividend Stocks Billionaire John Paulson Loves

5 Big Dividend Stocks Billionaire John Paulson Loves

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pushing The Health Services Industry Higher

3 Stocks Pushing The Health Services Industry Higher

3 Health Services Stocks Driving The Industry Higher

3 Health Services Stocks Driving The Industry Higher